trial

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

NCTId NCT03593213
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 587 (actual)
Sponsored by AbbVie
Primary completion 2021-02-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
587 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-07-30
Primary completion
2021-02-11
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

AbbVieLead Sponsor

Sites

97 total
Bentonville, United StatesLittle Rock, United StatesRogers, United StatesAnaheim, United StatesBellflower, United StatesCerritos, United StatesCosta Mesa, United StatesCosta Mesa, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLa Habra, United States

Linked catalysts

1
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine — primary completion2021-02-11

Facts & assertions

4 sourced
Enrollment
587
Phase
PHASE3
Primary Completion Date
2021-02-11
Status
TERMINATED
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia
indication